MCID: DMY004
MIFTS: 57

Demyelinating Disease

Categories: Neuronal diseases

Aliases & Classifications for Demyelinating Disease

MalaCards integrated aliases for Demyelinating Disease:

Name: Demyelinating Disease 12 76 15
Demyelinating Diseases 55 44 73
Demyelinating Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3213
MeSH 44 D003711
NCIt 50 C34527
ICD10 33 G37.9
UMLS 73 C0011303

Summaries for Demyelinating Disease

MalaCards based summary : Demyelinating Disease, also known as demyelinating diseases, is related to balo concentric sclerosis and neuromyelitis optica. An important gene associated with Demyelinating Disease is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolate mofetil and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is... more...

Related Diseases for Demyelinating Disease

Diseases related to Demyelinating Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 balo concentric sclerosis 32.7 AQP4 IFNB1 MBP MOG
2 neuromyelitis optica 31.9 AQP4 IL17A MBP MOG
3 acute transverse myelitis 31.7 AQP4 IL10 MMP9
4 allergic encephalomyelitis 30.7 CXCL10 MBP MOG PLP1
5 progressive multifocal leukoencephalopathy 30.7 CD40LG MBP TNF
6 encephalitis 30.5 AQP4 CCL2 CXCL10 IL1B MOG
7 acute disseminated encephalomyelitis 30.4 AQP4 IL10 MBP MOG
8 optic neuritis 30.4 AQP4 MBP MOG PLP1 TNF
9 spondyloarthropathy 1 30.3 CD40LG IL17A TNF
10 myelitis 30.2 AQP4 IL17A MBP MOG TNF
11 spondylitis 30.2 CD40LG IL17A TNF
12 intracranial hypertension 30.2 AQP4 CXCL10 IL1B TNF
13 vasculitis 30.2 CCL2 CD40LG ICAM1 TNF
14 hematopoietic stem cell transplantation 29.7 IFNG IL10 TNF
15 transverse myelitis 29.7 AQP4 IL10 IL17A MBP MMP9 TNF
16 myasthenia gravis 29.4 IFNG IL10 MBP TNF
17 brucellosis 29.3 CD40LG IFNG IL10 TNF
18 rheumatic disease 29.3 CD40LG IFNG IL10 IL1B TNF
19 viral encephalitis 29.2 CCL2 CXCL10 IL10 IL1B MBP TNF
20 neuritis 29.1 AQP4 CCL2 CXCL10 IFNG IL1B MBP
21 acquired immunodeficiency syndrome 29.0 CD40LG IFNG IL10 IL1B TNF
22 multiple sclerosis 28.5 AQP4 CCL2 CXCL10 ICAM1 IFNB1 IFNG
23 psoriasis 28.3 CCL2 CXCL10 ICAM1 IFNG IL10 IL17A
24 inflammatory bowel disease 28.1 CCL2 CXCL10 ICAM1 IFNG IL10 IL17A
25 optic atrophy with demyelinating disease of cns 11.9
26 meningovascular neurosyphilis 11.2 CD40LG MBP
27 post-vaccinal encephalitis 11.1 CD40LG MBP
28 central pontine myelinolysis 11.1
29 acute proliferative glomerulonephritis 11.0 CCL2 CD40LG ICAM1
30 epileptic encephalopathy, early infantile, 39 11.0
31 tertiary neurosyphilis 11.0 CD40LG CXCL10 MBP
32 asymptomatic neurosyphilis 11.0 CD40LG CXCL10 IL17A
33 zika fever 11.0 CD40LG IFNB1
34 pelvic inflammatory disease 10.9 CCL2 CD40LG MMP9
35 chronic follicular conjunctivitis 10.9 IL1B MMP9
36 heterophyiasis 10.9 CD40LG ICAM1
37 combined immunodeficiency, x-linked 10.9 CD40LG IL7R PTPRC
38 central nervous system tuberculosis 10.9 CXCL10 IL1B MMP9
39 herpes simplex virus keratitis 10.8 CCL2 ICAM1
40 purulent labyrinthitis 10.8 CCL2 IL1B
41 keratitis, hereditary 10.8 IL17A IL1B MMP9
42 acute salpingitis 10.8 CD40LG TNF TNFRSF1A
43 microvascular complications of diabetes 1 10.8 CCL2 ICAM1 MMP9
44 brain edema 10.8 AQP4 IL1B MMP9
45 rheumatoid lung disease 10.8 CD40LG IL17A TNF
46 leukodystrophy, demyelinating, adult-onset, autosomal dominant 10.8
47 stachybotrys chartarum 10.8 CCL2 IL1B TNF
48 osteosclerotic myeloma 10.8 CD40LG IL1B TNF
49 scleritis 10.8 CCL2 MMP9 TNF
50 jejunoileitis 10.8 CD40LG IL1B TNF

Graphical network of the top 20 diseases related to Demyelinating Disease:



Diseases related to Demyelinating Disease

Symptoms & Phenotypes for Demyelinating Disease

GenomeRNAi Phenotypes related to Demyelinating Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 IL1B TNF CD40LG TNFRSF1A ICAM1 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 IL1B NTF3 TNF CD40LG TNFRSF1A ICAM1
3 Reduced mammosphere formation GR00396-S 9.5 MOG NTF3 PLP1 PTPRC ABCD1 CCL2

MGI Mouse Phenotypes related to Demyelinating Disease:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.49 IL17A IL10 IFNB1 IFNG MOG MBP
2 immune system MP:0005387 10.49 IL17A IL10 IFNB1 IFNG MOG MBP
3 homeostasis/metabolism MP:0005376 10.45 IL17A IL10 IFNB1 IFNG MBP NTF3
4 cellular MP:0005384 10.39 IFNG IL10 IL7R MOG MBP MMP9
5 growth/size/body region MP:0005378 10.39 IFNG IL17A IL10 MOG MBP MMP9
6 mortality/aging MP:0010768 10.35 IFNG IL17A IL10 MBP NTF3 MMP9
7 behavior/neurological MP:0005386 10.33 IL10 IFNG MOG MBP MMP9 AQP4
8 nervous system MP:0003631 10.33 IL10 IFNB1 IFNG MOG MBP NTF3
9 cardiovascular system MP:0005385 10.32 IFNG IL10 IL1B MMP9 ICAM1 CD40LG
10 endocrine/exocrine gland MP:0005379 10.3 IFNG IL17A IL10 IL7R ICAM1 CD40LG
11 digestive/alimentary MP:0005381 10.22 IFNG IL17A IL10 MMP9 ICAM1 AQP4
12 neoplasm MP:0002006 10.13 IL10 IFNB1 IFNG MMP9 IL1B IL7R
13 muscle MP:0005369 10.11 IFNG IL10 MOG MMP9 ICAM1 PLP1
14 integument MP:0010771 10.1 IL10 IFNG MMP9 IL1B ICAM1 CD40LG
15 no phenotypic analysis MP:0003012 9.97 IL10 IFNG IL17A IFNB1 AQP4 TNF
16 reproductive system MP:0005389 9.96 IL10 IFNG MBP MMP9 CD40LG ABCD1
17 renal/urinary system MP:0005367 9.87 IFNG IL17A MMP9 AQP4 CD40LG PTPRC
18 respiratory system MP:0005388 9.81 IFNG IL17A IL10 MMP9 AQP4 TNF
19 skeleton MP:0005390 9.7 IFNG IL17A IFNB1 IL10 MMP9 IL1B
20 vision/eye MP:0005391 9.4 IL10 IFNG MOG MBP NTF3 MMP9

Drugs & Therapeutics for Demyelinating Disease

Drugs for Demyelinating Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 128794-94-5 5281078
2
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Early Phase 1 24280-93-1 446541
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
4
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2 504-24-5 1727
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Natalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 189261-10-7
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
8
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145155-23-3
9
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 65271-80-9 4212
10
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147245-92-9 3081884
11
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
12
Interferon beta-1a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 145258-61-3 6438354
13
Menthol Approved Phase 4,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
14
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 216503-57-0
15 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
17
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
18
Memantine Approved, Investigational Phase 4,Phase 2,Phase 3 19982-08-2 4054
19
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
20
Methotrexate Approved Phase 4,Phase 3,Early Phase 1 1959-05-2, 59-05-2 126941
21
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 69-65-8 453 6251
22
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
23
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
24
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
25
Montelukast Approved Phase 4,Phase 1,Phase 2 158966-92-8 5281040
26
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
27
Acyclovir Approved Phase 4,Phase 3,Phase 1 59277-89-3 2022
28
Cetirizine Approved Phase 4,Phase 1,Phase 2 83881-51-0 2678
29
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
30
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
31
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
32
Ranitidine Approved Phase 4,Phase 3 66357-59-3, 66357-35-5 3001055
33
Aspirin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1 50-78-2 2244
34
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
35
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
36
Ethanol Approved Phase 4,Phase 3 64-17-5 702
37
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
38
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
39
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
40
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
41
Iron Approved Phase 4,Early Phase 1 7439-89-6 23925
42
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
43
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
44
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
45
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
46 Piracetam Approved, Investigational Phase 4 7491-74-9
47
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
48
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
49
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
50
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971

Interventional clinical trials:

(show top 50) (show all 1876)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Unknown status NCT02849782 Phase 4 Fampridine
3 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Unknown status NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
5 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
6 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4 Fingolimod;Natalizumab
7 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
8 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4 SR-fampridine;Placebo
9 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
10 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4 Dietary Supplement: vitamin A;placebo
11 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4 Drug: placebo
12 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
13 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
14 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
15 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4 glatiramer acetate
16 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
17 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
18 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
19 A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed NCT01715831 Phase 4 DMARDs;Tocilizumab
20 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
21 Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy Completed NCT03091569 Phase 4
22 Natalizumab Temporary Discontinuation Study Completed NCT02775110 Phase 4
23 Tecfidera and the Gut Microbiota Completed NCT02471560 Phase 4 dimethyl fumarate;injectable MS DMT
24 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4 extended release fampridine;Placebo
25 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia Completed NCT01556685 Phase 4
26 A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® Completed NCT00239993 Phase 4 glatiramer acetate
27 BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Completed NCT03269175 Phase 4
28 Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) Completed NCT02720107 Phase 4
29 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
30 Plegridy Satisfaction Study in Participants Completed NCT02587065 Phase 4 peginterferon beta-1a
31 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Completed NCT02499900 Phase 4 Copaxone®
32 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera Completed NCT02410278 Phase 4 dimethyl fumarate;montelukast;Placebo
33 Fingolimod Effect on Cytokine and Chemokine Levels Completed NCT02373098 Phase 4 Fingolimod 0.5 mg
34 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
35 Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Completed NCT02205489 Phase 4 Alemtuzumab GZ402673;cetirizine;ranitidine;methylprednisolone;methylprednisolone;aciclovir;esomeprazole;ibuprofen;paracetamol
36 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
37 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4 dimethyl fumarate
38 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4 dimethyl fumarate;acetylsalicylic acid;ASA-Placebo
39 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4 Rebif®;Rebif®
40 Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS Completed NCT02048072 Phase 4 Gilenya
41 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
42 Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse Completed NCT01986998 Phase 4 Methylprednisolone 1250 mg/24h x3 days;Oral Methylprednisolone 625 mg/24h x3 days
43 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
44 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
45 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
46 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
47 Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations Completed NCT01888354 Phase 4 H.P. Acthar Gel (repository corticotropin injection)
48 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4 BG00012 (DMF)
49 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
50 Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications Completed NCT01834586 Phase 4 Anesthetic Topical Adhesive Synera

Search NIH Clinical Center for Demyelinating Disease

Cochrane evidence based reviews: demyelinating diseases

Genetic Tests for Demyelinating Disease

Anatomical Context for Demyelinating Disease

MalaCards organs/tissues related to Demyelinating Disease:

41
Brain, Testes, Bone, T Cells, Spinal Cord, Bone Marrow, Skin

Publications for Demyelinating Disease

Articles related to Demyelinating Disease:

(show top 50) (show all 197)
# Title Authors Year
1
Demyelinating disease: Cholesterol crystals thwart repair in old CNS. ( 29391584 )
2018
2
Mast Cells and Innate Lymphoid Cells: Underappreciated Players in CNS Autoimmune Demyelinating Disease. ( 29619025 )
2018
3
Occipital neuralgia associates with high cervical spinal cord lesions in idiopathic inflammatory demyelinating disease. ( 29629601 )
2018
4
Dissecting the multifactorial nature of demyelinating disease. ( 29722306 )
2018
5
Correction to: Protective and therapeutic role of 2-carbacyclic phosphatidic acid in demyelinating disease. ( 29506553 )
2018
6
microRNA-219 Reduces Viral Load and Pathologic Changes in Theiler's Virus-Induced Demyelinating Disease. ( 29433936 )
2018
7
Neutropenia as a Complication of Tumefactive Demyelinating Disease: A Case Report. ( 29330070 )
2018
8
Effects of Keratinocyte-Derived Cytokine (CXCL-1) on the Development of Theiler's Virus-Induced Demyelinating Disease. ( 29410948 )
2018
9
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. ( 29421990 )
2018
10
MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. ( 29438836 )
2018
11
Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-I^ signaling. ( 29662171 )
2018
12
Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses. ( 29362931 )
2018
13
CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. ( 29455184 )
2018
14
Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. ( 29856159 )
2018
15
Migraine as possible red flag of PFO presence in suspected demyelinating disease. ( 29801894 )
2018
16
Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease. ( 28732510 )
2017
17
Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. ( 28533776 )
2017
18
The many faces of demyelinating diseases: acute disseminated encephalomyelitis and Guillain-BarrAc syndrome in the same patient. ( 28591395 )
2017
19
Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. ( 28104248 )
2017
20
CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. ( 28657431 )
2017
21
Demyelinating disease: Astrocyte stress precedes demyelination in cerebral X-ALD. ( 28387337 )
2017
22
Prostaglandin E2 produced following infection with Theiler's virus promotes the pathogenesis of demyelinating disease. ( 28445497 )
2017
23
Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen. ( 28484224 )
2017
24
Human Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease. ( 28793252 )
2017
25
Central and peripheral nervous system immune-mediated demyelinating disease after allogeneic hematopoietic stem cell transplantation. ( 28495143 )
2017
26
The balance between cathepsin C and cystatin F controls remyelination in the brain of Plp1-overexpressing mouse, a chronic demyelinating disease model. ( 28251676 )
2017
27
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 28535894 )
2017
28
Vascular hypoperfusion in acute optic neuritis is a potentially new neurovascular model for demyelinating diseases. ( 28926646 )
2017
29
AhR-deficiency as a cause of demyelinating disease and inflammation. ( 28851966 )
2017
30
DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. ( 28929835 )
2017
31
Treatment of Theiler's virus-induced demyelinating disease with teriflunomide. ( 28913765 )
2017
32
NFM Cross-Reactivity to MOG Does Not Expand a Critical Threshold Level of High-Affinity T Cells Necessary for Onset of Demyelinating Disease. ( 28887429 )
2017
33
Citation classics in central nervous system inflammatory demyelinating disease. ( 28638708 )
2017
34
MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. ( 28284341 )
2017
35
Clinical features in very early-onset demyelinating disease with anti-MOG antibody. ( 28551039 )
2017
36
Recruitment of endogenous CNS stem cells for regeneration in demyelinating disease. ( 28554395 )
2017
37
Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. ( 27746022 )
2016
38
An Occult Malignancy Behind a Demyelinating Disease: POEMS Syndrome. ( 27790622 )
2016
39
The role of growth factors as a therapeutic approach to demyelinating disease. ( 27016070 )
2016
40
Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease. ( 26791341 )
2016
41
Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population. ( 26951408 )
2016
42
The role of I+4 integrin in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease: an infectious animal model for multiple sclerosis (MS). ( 27803063 )
2016
43
Serum concentration of CD40L is elevated in inflammatory demyelinating diseases. ( 27725124 )
2016
44
Germinoma Mimicking Tumefactive Demyelinating Disease in Pediatric Patients. ( 26811911 )
2016
45
Comparison of Cerebrospinal Fluid Opening Pressure in Children With Demyelinating Disease to Children With Primary Intracranial Hypertension. ( 27909013 )
2016
46
The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease. ( 27519147 )
2016
47
FLT PET/CT in a Case of Demyelinating Disease. ( 27088385 )
2016
48
Demyelinating disease: Novel markers for disease severity in neuromyelitis optica. ( 27020559 )
2016
49
Intractable Hiccup in Demyelinating Disease with Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody. ( 27725560 )
2016
50
Association Between the Single Nucleotide Polymorphism and the Level of Aquaporin-4 Protein Expression in Han and Minority Chinese with Inflammatory Demyelinating Diseases of the Central Nervous System. ( 25895050 )
2016

Variations for Demyelinating Disease

Expression for Demyelinating Disease

Search GEO for disease gene expression data for Demyelinating Disease.

Pathways for Demyelinating Disease

Pathways related to Demyelinating Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CCL2 CD40LG CXCL10 ICAM1 IFNB1 IFNG
2
Show member pathways
13.91 CCL2 CD40LG CXCL10 IL10 IL17A IL1B
3
Show member pathways
13.77 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
4
Show member pathways
13.59 CCL2 IFNB1 IFNG IL10 IL17A IL1B
5
Show member pathways
13.5 CCL2 CD40LG CXCL10 IL10 IL17A IL1B
6
Show member pathways
13.38 CCL2 CD40LG CXCL10 IL10 IL17A IL1B
7
Show member pathways
13.36 CCL2 CD40LG CXCL10 ICAM1 IFNB1 IFNG
8
Show member pathways
13.11 CCL2 CXCL10 IFNB1 IFNG IL10 IL1B
9
Show member pathways
12.98 CD40LG ICAM1 IFNG IL10 IL17A IL1B
10
Show member pathways
12.92 CCL2 MMP9 PTPRC TNF TNFRSF1A
11
Show member pathways
12.9 CCL2 CXCL10 ICAM1 IFNB1 IFNG IL1B
12
Show member pathways
12.8 CXCL10 IFNB1 IFNG IL1B TNF
13
Show member pathways
12.76 IFNB1 IFNG IL10 IL17A IL1B IL7R
14
Show member pathways
12.75 CD40LG IL1B NTF3 TNF TNFRSF1A
15